LENSAR (LNSR) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sera Prognostics (SERA) has outperformed LENSAR (LNSR) over the past year, losing 35.9% versus a loss of 47.0%. Over five years, LNSR leads with a -14.2% price change compared with -81.4% for SERA. Sera Prognostics is the larger company by market cap ($81.3 million vs $78.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNSR | SERA |
|---|---|---|
| Share price | $6.39 | $2.06 |
| Market cap | $78.51M | $81.27M |
| 1-day change | -0.93% | +1.98% |
| YTD return | -44.54% | -31.53% |
| 1-year return | -47.04% | -35.87% |
| 5-year return | -14.23% | -81.38% |
| P/E ratio (TTM) | 35.50 | — |
| EPS (TTM) | $0.18 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.94 | $3.95 |
| 52-week low | $4.95 | $1.56 |
| Distance from 52-week high | -50.62% | -47.85% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +77.31% | +166.99% |
| Average volume | 102.04K | 27.84K |
| Shares outstanding | 12.29M | 38.48M |
| Employees | 150 | 71 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SERA has outperformed LNSR by 11.2 percentage points over the past year.
About LENSAR
LNSR stock →LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
Health Care · Medical/Dental Instruments · 150 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Health Care · Medical Specialities · 71 employees
LNSR vs SERA FAQ
Which is bigger, LENSAR or Sera Prognostics?
Sera Prognostics (SERA) is larger, with a market capitalization of $81.27M compared with $78.51M for LENSAR (LNSR).
Which stock has performed better over the past year, LNSR or SERA?
SERA returned -35.87% over the past 12 months, compared with -47.04% for LNSR (price return, excluding dividends). Past performance does not predict future results.
Are LENSAR and Sera Prognostics in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for LENSAR and Medical Specialities for Sera Prognostics.